Jobs / United States / Sanofi US Services INC
Head of Platform Technologies MSAT Recombinant Mammalian Drug Substance CoE
Sanofi US Services INC · 🇺🇸 Framingham, MA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Sanofi US Services INC
The US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Sanofi US Services INC →
About the role
Job Title : Head of Platform Technologies, MSAT Recombinant Mammalian Drug Substance CoE • Location: Framingham, MA About the Job Sanofi Global MSAT (Manufacturing Sciences, Analytics, and Technology) acts as a crucial link between our R&D and Manufacturing facilities, playing a vital role in securing the present portfolio and delivering future launches of high-quality and innovative drugs and vaccines. By driving its own transformation, Global MSAT fulfils an important function by providing day-to-day Manufacturing Support, focusing on technical and process aspects, effective Life Cycle Management, process robustness enhancement, and yield improvement to optimize performance. Join our global network and contribute to the launch of 3 to 5 new products annually across various modalities, enabling us to reach and serve more patients and communities. Collaborate with a team of talented and passionate international experts, scientists, and project leaders who are dedicated to inventing, designing, and implementing cutting-edge industrial chemical and biological processes, analytical methods, and process modelling, all in support of Sanofi’s best-in-class ambition. The Head of Platform Technologies will lead a dynamic team of Subject Matter Experts within the MSAT Recombinant Mammalian Center of Excellence (CoE), located at Sanofi’s Massachusetts Framingham Bio-Campus. This team is responsible for establishing state‑of‑the‑art innovation laboratory infrastructures and enabling next‑generation platform technologies, including perfusion cell culture and continuous purification processes. This senior leadership role will support implementation strategies for commercial programs by collaborating closely with R&D, Manufacturing, and external partners. The team will also spearhead global MSAT innovation initiatives across platforms in partnership with other MSAT groups, while representing MSAT’s scientific leadership and excellence in both internal and external forums. We deliver 4.3 billion healthcare solutions to people every year, thanks to the flawless planning and meticulous eye for detail of our Manufacturing & Supply teams. With your talent and ambition, we can do even more to protect people from infectious diseases and bring hope to patients and their families. About Sanofi: We’re an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our deep understanding of the immune system and innovative pipeline enables us to invent medicines and vaccines that treat and protect millions of people around the world. Together, we chase the miracles of science to improve lives. *Hybrid Schedule - 3 days per week onsite- required. * Main Responsibilities The Head of Platform Technologies will lead a Subject Matter Experts (SME) team to deliver the following core objectives: • Lead the evaluation of Sanofi’s next‑generation platform technologies including perfusion cell culture, continuous purification, advanced Process Analytical Technology (PAT), smart manufacturing, and emerging novel process chemistries. Develop the MSAT position on development data package requirements, at‑scale operational readiness, transferability, lab‑scale model expectations, and MSAT training and expertise needs. Ensure alignment of platform‑technology initiatives with broader organizational objectives such as 2nd‑generation program development, process robustness, and yield improvement. • Establish and maintain cutting‑edge innovation laboratory infrastructures within the COE. Partner with upstream, downstream, and analytical teams to advance lab digitization and automation. Build additional laboratory and pilot‑scale capabilities that embody Sanofi’s smart‑lab future concept. • Build and maintai